News
Women In Science: Inspiring the Next Generation
On the International Day of Women in Science, we celebrate the brilliant minds of women shaping the future of science.
See more
Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in Europe and the USA
Framatome and IBA today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.
See more
Trends for Nuclear Medicine in 2025
Discover our new series with Prof Dr Rudi Dierckx, a globally renowned expert. The field of Nuclear Medicine is experiencing continuous growth driven by an increasing clinical demand for diagnosis and therapies. Through short capsules weekly published, Prof Dr Rudi Dierckx delves into the major trends shaping the field in 2025.
See more
LIVE WEBINAR 27/01 | Targeted Alpha Therapy: Navigating the Path to Clinical Implementation and Future Outlook
LIVE WEBINAR 27/01/2025 - IBA RadioPharma Solutions | Targeted Alpha Therapy: Navigating the Path to Clinical Implementation and Future Outlook | Prof Dr Giesel & Prof Dr Levillain
See more
Best wishes from our entire IBA RadioPharma Solutions team!
Best wishes from our entire IBA RadioPharma Solutions team!
See more
AlF-peptides labelling method - One process to label them all…
IBA intend to propose commercial kits for AlF-peptide process on Synthera®+ (IFP, reagents, ancillaries)
See more![[18F]F-rhPSMA-7.3](https://hm-offload.s3.eu-west-3.amazonaws.com/iba/2024/12/PSMA-1.jpg)
18F-flotufolastat (previously known as 18F rhPSMA-7.3)
Automated labeling of flotufolastat gallium triflutate with 18F on the IBA Synthera®+ Platform - a simplified and efficient approach
See more
[18F]FES /16α-[18F]-fluoroestradiol
[18F]luoroestradiol / [18F]FES /16α-[18F]-fluoroestradiol. Radiolabeled analog of estradiol used as a contrast agent in the PET imaging of estrogen receptor-positive breast cancer lesions.
See moreIBA Reports Third Quarter 2024 Results
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the third quarter 2024.
See more